References
- Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol. 2012;23(Suppl 6):vi7–12. doi:https://doi.org/10.1093/annonc/mds187.
- Dietze EC, Sistrunk C, Miranda-Carboni G, O’Regan R, Seewaldt VL. Triple-negative breast cancer in African-American women: disparities versus biology. Nat Rev Cancer. 2015;15:248–54. doi:https://doi.org/10.1038/nrc3896.
- Dawson SJ, Provenzano E, Caldas C. Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer. 2009;45(Suppl 1):27–40. doi:https://doi.org/10.1016/S0959-8049(09)70013-9.
- Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im S-A, Shaw Wright G, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–21. doi:https://doi.org/10.1056/NEJMoa1809615.
- Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395–99. doi:https://doi.org/10.1038/nature10933.
- Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–92. doi:https://doi.org/10.1056/NEJMoa1113205.
- Selvaraj P, Yerra A, Tein L, Shashidharamurthy R. Custom designing therapeutic cancer vaccines: delivery of immunostimulatory molecule adjuvants by protein transfer. Hum Vaccin. 2008;5:1–5.
- Croce MV, Segal-Eiras A. The use of carbohydrate antigens for the preparation of vaccines for therapy in breast cancer. Drugs Today (Barc). 2002;38:759–68. doi:https://doi.org/10.1358/dot.2002.38.11.820135.
- Croce MV, Rabassa ME, Pereyra A, Segal-Eiras A. Differential expression of MUC1 and carbohydrate antigens in primary and secondary head and neck squamous cell carcinoma. Head Neck. 2008;30:647–57. doi:https://doi.org/10.1002/hed.20756.
- Livingston PO, Ragupathi G, Musselli C. Autoimmune and antitumor consequences of antibodies against antigens shared by normal and malignant tissues. J Clin Immunol. 2000;20:85–93. doi:https://doi.org/10.1023/A:1006697728855.
- McHugh RS, Nagarajan S, Wang YC, Sell KW, Selvaraj P. Protein transfer of glycosylphosphatidylinositol-B7-1 into tumor cell membranes: A novel approach to tumor immunotherapy. Cancer.Res. 1999;59:2433–37.
- Poloso NJ, Nagarajan S, Bumgarner GW, Selvaraj P. Development of therapeutic vaccines by direct modification of cell membranes from surgically removed human tumor tissue with immunostimulatory molecules. Vaccine. 2001;19:[pii] 2029–2038. doi:https://doi.org/S0264-410X(00)00424-2.
- Nagarajan S, Selvaraj P. Human tumor membrane vesicles modified to express glycolipid-anchored IL-12 by protein transfer induce T cell proliferation in vitro: A potential approach for local delivery of cytokines during vaccination. Vaccine. 2006;24:2264–74. doi:https://doi.org/10.1016/j.vaccine.2005.11.045.
- Patel JM, Vartabedian VF, Bozeman EN, Caoyonan BE, Srivatsan S, Pack CD, Dey P, D'Souza MJ, Yang L, Selvaraj P. Plasma membrane vesicles decorated with glycolipid-anchored antigens and adjuvants via protein transfer as an antigen delivery platform for inhibition of tumor growth. Biomaterials. 2015;74:231–44. doi:https://doi.org/10.1016/j.biomaterials.2015.09.031.
- Liu G, Tarbet B, Song L, Reiserova L, Weaver B, Chen Y, Li H, Hou F, Liu X, Parent J, et al. Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice. PLoS One. 2011;6(6):e20928. doi:https://doi.org/10.1371/journal.pone.0020928.
- Zhu M, Ding X, Zhao R, Liu X, Shen H, Cai C, Ferrari M, Wang HY, Wang R-F. Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma. J Controlled Release. 2018;272(72–82):72–82. doi:https://doi.org/10.1016/j.jconrel.2018.01.004.
- Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature. 2006;440(808–812):808–12. doi:https://doi.org/10.1038/nature04596.
- Bates JT, Graff AH, Phipps JP, Grayson JM, Mizel SB. Enhanced antigen processing of flagellin fusion proteins promotes the antigen-specific CD8+ T cell response independently of TLR5 and MyD88. J Immunol. 2011;186:6255–62. doi:https://doi.org/10.4049/jimmunol.1001855.
- Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. Curr Protoc Immunol. 2001;20:20.2. doi:https://doi.org/10.1002/0471142735.im2002s39.
- Kaur P, Nagaraja GM, Zheng H, Gizachew D, Galukande M, Krishnan S, Asea A. A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease. BMC Cancer. 2012;12:120. doi:https://doi.org/10.1186/1471-2407-12-120.
- Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun. 2013;13:5.
- Patel JM, Kim MC, Vartabedian VF, Lee YN, He S, Song JM, Choi HJ, Yamanaka S, Amaram N, Lukacher A, et al. Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses. Nanomed. 2015;11(1097–1107). doi:https://doi.org/10.1016/j.nano.2015.02.008
- Waitz R, Solomon SB, Petre EN, Trumble AE, Fasso M, Norton L, Allison JP. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res. 2012;72:430–39. doi:https://doi.org/10.1158/0008-5472.CAN-11-1782.
- Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1(2315–2319). doi:https://doi.org/10.1038/nprot.2006.339.
- Song Y, Xue L, Du S, Sun M, Hu J, Hao L, Gong L, Yeh D, Xiong H, Shao S, et al. Caveolin-1 knockdown is associated with the metastasis and proliferation of human lung cancer cell line NCI-H460. Biomed Pharmacother. 2012;66(6):439–47. doi:https://doi.org/10.1016/j.biopha.2012.03.001.
- Yiu HH, Graham AL, Stengel RF. Dynamics of a cytokine storm. PLoS One. 2012;7:e45027. doi:https://doi.org/10.1371/journal.pone.0045027.
- Bozeman EN, Cimino-Mathews A, Machiah DK, Patel JM, Krishnamoorthy A, Tien L, Shashidharamurthy R, Selvaraj P. Expression of membrane anchored cytokines and B7-1 alters tumor microenvironment and induces protective antitumor immunity in a murine breast cancer model. Vaccine. 2013;31:2449–56. doi:https://doi.org/10.1016/j.vaccine.2013.03.028.
- Cimino AM, Palaniswami P, Kim AC, Selvaraj P. Cancer vaccine development: protein transfer of membrane-anchored cytokines and immunostimulatory molecules. Immunol.Res. 2004;29:231–40. doi:https://doi.org/10.1385/IR:29:1-3:231.
- Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E, et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019;565(7738):234–39. doi:https://doi.org/10.1038/s41586-018-0792-9.
- Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAAS, Andrews MC, Sharma P, Wang J, Wargo JA, Pe’er D, et al. Distinct cellular mechanisms underlie Anti-CTLA-4 and Anti-PD-1 checkpoint blockade. Cell. 2017;170(6):1120–1133.e1117. doi:https://doi.org/10.1016/j.cell.2017.07.024.
- Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, Shan Q, Hale JS, Lee J, Nasti TH, et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature. 2016;537(7620):417–21. doi:https://doi.org/10.1038/nature19330.
- Crosby EJ, Wei J, Yang XY, Lei G, Wang T, Liu C-X, Agarwal P, Korman AJ, Morse MA, Gouin K, et al. Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors. Oncoimmunology. 2018;7(5):e1421891. doi:https://doi.org/10.1080/2162402x.2017.1421891.
- Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. doi:https://doi.org/10.1056/NEJMoa1003466.
- Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734–36. doi:https://doi.org/10.1126/science.271.5256.1734.
- Quezada SA, Peggs KS, Simpson TR, Allison JP. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev. 2011;241:104–18. doi:https://doi.org/10.1111/j.1600-065X.2011.01007.x.